Jaguar Animal Health (NASDAQ:JAGX) vs. Tilray Brands (NASDAQ:TLRY) Head-To-Head Comparison

Tilray Brands (NASDAQ:TLRY) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Tilray Brands and Jaguar Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-16.91%	-10.39%	-7.38%
Jaguar Animal Health	-187.88%	N/A	-131.45%

Insider & Institutional Ownership

9.3% of Tilray Brands shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 1.6% of Tilray Brands shares are held by insiders. Comparatively, 0.1% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Tilray Brands has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tilray Brands and Jaguar Animal Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45 million	0.45	-$121.40 million	($1.40)	-2.01
Jaguar Animal Health	$11.51 million	0.07	-$53.43 million	($3,731.33)	-0.00

Jaguar Animal Health has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tilray Brands and Jaguar Animal Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	3	1	2.38
Jaguar Animal Health	1	0	0	0	1.00

Tilray Brands presently has a consensus target price of $5.90, suggesting a potential upside of 109.96%. Given Tilray Brands’ stronger consensus rating and higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Jaguar Animal Health.

Summary

Tilray Brands beats Jaguar Animal Health on 11 of the 14 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.